首页>>国际

2022年8月10日重庆市新冠肺炎疫情情况

2022-08-10 13:01:34 | 来源:广德新闻网
小字号

8月9日0—24时,重庆市新增本土确诊病例1例(渝北区),在重点人员核酸检测中发现;新增本土无症状传染者2例,此中,丰都县1例(在重点人员核酸检测中发现)、南岸区1例(在隔离管控人员中发现)。截至8月9日24时,重庆市现有本土确诊病例20例(江津区2例、长命区2例、合川区6例、沙坪坝区4例、九龙坡区4例、南岸区1例、渝北区1例),现有本土无症状传染者20例(万盛经开区1例、合川区9例、沙坪坝区2例、九龙坡区4例、南岸区3例、丰都县1例)。8月9日0—24时,重庆市新增境外输入确诊病例1例(新加坡),新增境外输入无症状传染者1例(新加坡)。截至8月9日24时,重庆市现有境外输入确诊病例7例(中国喷鼻港1例、新加坡6例),现有境外输入无症状传染者3例(新加坡2例、泰国1例)。重庆市8月9日新增本土确诊病例和本土无症状传染者根基环境以下:1、渝北区渝北区确诊病例1,系市外重点地域返渝人员。8月9日,按照尝试室查抄成果、影象学特点和临床症状,经专家组会诊,诊断为新冠肺炎确诊病例(轻型)。2、丰都县丰都县无症状传染者1,系市外重点地域返渝人员。8月9日,按照尝试室查抄成果、影象学特点和临床症状,经专家组会诊,鉴定为无症状传染者。3、南岸区南岸区无症状传染者3,系南岸区确诊病例1的紧密亲密接触者。8月9日,按照尝试室查抄成果、影象学特点和临床症状,经专家组会诊,鉴定为无症状传染者。重庆市8月9日新增境外输入确诊病例根基环境以下:该病例重新加坡乘坐SQ814次航班,于2022年8月8日抵达重庆,即被送至集中隔离点接管医学察看。8月9日,按照尝试室查抄成果、影象学特点和临床症状,经专家组会诊,诊断为新冠肺炎确诊病例(轻型)。 亲爱的用户,“重庆”客户端现已正式改版进级为“新重庆”客户端。为不影响后续利用,请扫描上方二维码,实时下载新版本。更优良的内容,更便捷的体验,我们在“新重庆”等你!

(责编:adkin)

分享让更多人看到

揭秘!宜昌楼凤(更多内幕请戳)

深圳试点个人破产制度改革一年收到申请1031件

2022-08-10 12:58:35 | 来源:景德镇市新闻网
小字号

  深圳小我破产轨制鼎新实行一年多,试点环境有了新进展。截至本年2月28日,深圳中院共收到小我破产申请1031件,每个月平均收到申请近86件。申请人的债务范围最小约1.8万元,最年夜约16亿元。57.5%的申请人有创业掉败或经营不善履历……  近日,深圳破产法庭庭长曹启选等在最高人平易近法院机关刊《人平易近司法》颁发文章《小我破产轨制先行先试中的实践示范与系统构建》(下称“文章”),系统介绍了小我破产审讯环境。自从客岁3月1日《深圳经济特区小我破产条例》(下称“条例”)实施以来,深圳中院在小我破产案件审理中,慢慢了了启动重整、息争、破产清理法式和不予受理的梯度审查尺度,增强“多重整息争,少破产清理”的司法政策指导,确保“老实而不幸”的债务人进入破产法式取得轨制布施。  债务人画像  遭受财政掉败、处于债务危机的社会主流人群  从1031件破产申请样原本看,超七成的申请人处于30—50岁的青丁壮期间,欠债缘由八成是出产经营和糊口消费,跨越一半的申请人欠债在100万元以下。文章总结,小我破产债务人整体显现出主体为有工作能力或必然资产、可以或许从银行取得授信可是遭受了财政掉败、处于债务危机的社会主流人群。  文章还罗列了很多有价值的参考数据。欠债缘由方面,债务人欠债的重要缘由为出产经营,次要缘由为糊口消费。此中,有创业掉败或经营不善履历的破产申请593件,占比57.5%,但此中糊口欠债跨越总欠债一半的有119件;纯洁因糊口欠债而提起的破产申请221件,占21.4%;因投契、侵权、欺骗、赌钱行动而欠债的破产申请176件,占17.1%。  债务范围方面,最小约1.8万元,最年夜约16亿元,债务人欠债中位数为91.31万元。欠债100万元以下546人,占全数申请数的53.0%;欠债100万元至500万元371人,占36.0%;欠债500万元至1000万元46人,占4.5%;欠债1000万元以上68人,占6.6%,此中8人欠债过亿,首要由于公司经营承当连带担保责任。  面谈教导机制  破产法官对申请人进行  一对一面谈教导  从深圳中院一年多的实践来看,不管是回应小我债务纾困的实际需求,仍是知足社会对反破产讹诈的规制保障,小我破产轨制的实行都需要解决诸多问题。针对这些问题,法院在司法裁判层面都落实了针对性办法。  起首,债务人对破产轨制的认知仍有不足,提交的资料常常不齐备,增添了破产缘由审查难度。对此,深圳中院立异面谈教导机制,由破产法官对申请人进行一对一面谈教导,让债务人清楚领会小我破产完全法式、取得布施的本钱和法令后果。  经由过程面谈教导和听证审查,法院慢慢确立了破产缘由审查法则,明白了法式启动前提,也为破产事务治理署顺遂承接咨询教导本能机能、成立申请前教导机制堆集经验。  其次,绝年夜大都债务人在申请破产时,遍及迫于债务压力,直接选择最耳熟能详的破产清理,对破产重整、破产息争两种方案缺少谨慎评估和综合斟酌。  “因为立法时缺少实证撑持,条例没有为小我破产清理、重整、息争3个法式设定分歧的准入前提。”曹启选介绍,在司法实践中,深圳中院对峙破产轨制的解救功能,在审查尺度和法式准入上,表现出光鲜的重整息争优先的司法政策导向。  指导结果若何?文章列出数字左证,申请重整、息争的债务人比例从条例实行首月的10%上升至一年后的23.4%。深圳破产法庭在本年5月17日发布《增强小我破产申请和审查工作的实行定见》进一步明白,申请小我破产清理的债务人,该当合适损失了债能力且了债能力不成恢复的前提。  打造“四位一体”系统  重塑破产法式各本能机能脚色,  完美反讹诈机制  在多年企业破产实践的根本上,深圳充实接收国际经验,依托小我破产试点鼎新,以破产案件审讯权与破产事务治理权的分手为引线,率先成立法院裁判、当局监管、治理人履行、公家监视“四位一体”的破产打点系统。  客岁3月1日,全国首个破产事务治理机构——深圳市破产事务治理署正式挂牌成立,承当破产事务行政治理本能机能。在保障法式介入主体和公家知情权方面,客岁8月18日,深圳中院、深圳市市场监视治理局、深圳市破产事务治理署配合成立全国首个破产信息公然轨制,笼盖企业和小我等破产主体,增强信誉束缚,全流程监视破产信息公然。  自此,深圳小我破产鼎新重塑了破产法式中各本能机能脚色的定位,即法院负责破产审讯,破产事务治理机构负责破产事务监管,治理人在个案中负责具体事务和法式推动,公家经由过程破产信息公然轨制实现普遍监视。  曹启选介绍,为回应社会公家对滥用小我破产轨制逃废债的耽忧,条例及其实行出力完美反破产讹诈机制,确保法院、当局、治理人、债权人多主体各司其职,构成监视追责协力。  南边日报记者 杜玮淦

(责编:adkin)

分享让更多人看到

Asia Cell & Gene Therapy Innovation Summit 2022
  • #CGT Asia 2022
  • August 9th-10th
  • Shanghai China

Asia Cell & Gene Therapy Innovation Summit 2022

0 +

Keynote
Speeches

0 +

Professional
Attendees

0 +

Featured
Booths

0 +

Global Cell&Gene
Therapy Enterprises

0 +

Media
Reports

Key words of the conference

Cell Therapy, Gene Therapy, Innovative Therapy, Next Generation Oncolytic Virus, End to End Development, CDMO, CRO, Regulation, IND Application, GLP, Clinical Trail Design, Continuous Production Process, GMP, Immunomodulation, Viral Vectors, High-Throughput Screening, Transfection, Combination Therapy, IVD, Digital PCR, CRISPR/CAS9 Gene Editing, Humanized Animal models, mRNA Tumor Vaccines, Nanoantibody, BsAbs, Customization Manufacturing, Tumor Microenvironment, Stem Cell Therapy, Recombinant Protein, Targets

Event Highlights

Cell Therapy Industrialization and Commercialization Module Strategy

TCR-T Therapy Market Prospects and Development Trends

Targets Selection and Direction of TCR-T Therapeutic Products

Development Key Points of Universal CAR-NK Cell Therapy Products

iPSC Personalized Diagnosis and Treatment and Application

Research and Development of mRNA Drug and Delivery Vector Technology

Viral Vector Process and Optimization Plan

Difficulty in the Development of Gene Therapy Drugs for Rare Diseases

Current Status of Circular RNA R&D

Who Should Attend

Biopharmaceutical CompaniesPre-Clinical R&DClinical R & DVaccine/Antibody CompaniesCell Therapy CompaniesGene Therapy CompaniesScientific Research InstitutesBiotechnology CompaniesLaboratory Equipment SuppliersDrug TestingAnalytical ServicesProduction Solution Providers (Upstream, Downstream) Life Science and Analytical EquipmentDiagnostic and Testing EquipmentExternal AuthorizationProtein Drugs CompaniesContract Service Providers (CRO, CMO, CDMO) Import and Export EnterprisesHVAC Facilities and Cleanroom Equipment SuppliersGovernment Representatives/Trading InstitutionsPreparation MachineryPharmaceutical EngineeringLaw and Regulation FirmsDrug Delivery System ManufacturersThird Party Logistics ProvidersAutomation/RobotCold Chain Packaging CompaniesPackaging MachineryIndustrial ParksLaboratory ServicesLaboratory/Biochemical/Analytical InstrumentsFine Chemical ManufacturersEnvironmental ProtectionIntermediate ManufacturersRegulatory ServicesSupply ChainNew Drug R & D CompaniesConsultant Companies


Exhibition & Show
Exhibition & Show
Exhibition & Show
Exhibition & Show
Exhibition & Show
Exhibition & Show
Exhibition & Show


Speakers

Dr. Xingwang XIE
Dr. Xingwang XIE

CEO

Corregene

Dr. Guojie YE
Dr. Guojie YE

CSO

EXEGENESIS BIO

Dr. Jinghui DOU
Dr. Jinghui DOU

CSO

TriApex Laboratories Co. LTD

Dr. Wenqiang YU
Dr. Wenqiang YU

Senior PI

Institutes of Biomedical Sciences Fudan University

Yan CHANG
Yan CHANG

President

INNOSTAR - National Shanghai Center for New Drug Safety Evaluation and Research

Dr. Xinpo JIANG
Dr. Xinpo JIANG

Associate Vice President, R&D, Catalog Product

GenScript

Mr. Hongdong YU
Mr. Hongdong YU

Director of Biological Culture Scenario

Haier Biomedical

Xiaochun Wan
Xiaochun Wan

CEO

Shenzhen BinDeBio Ltd.

Kangjian ZHANG
Kangjian ZHANG

Co-Founder, Director and GM

Yuansong Bio

Dr. Andrew LIN
Dr. Andrew LIN

Founder & CEO

Lingyi Biotherapeutics Co. Ltd

Mo MA
Mo MA

CEO

Shenzhen Eureka Biotechnology Co., Limited

Dr. Jinqiao WAN
Dr. Jinqiao WAN

Vice President of R&D Chemistry Center

HitGen Inc.

Chunying Li
Chunying Li

Technical Application Liaison, China

Mission Bio

Hongjiu DAI
Hongjiu DAI

CEO

Nanjing Kaedi Biotherapeutics

Prof. Evelyne Yehudit Bischof
Prof. Evelyne Yehudit Bischof

Professor Doctor

Shanghai University of Medicine and Health Sciences

Yongzhen LIU
Yongzhen LIU

Deputy Director of Center for Drug Safety Evaluation

Shanghai Institute of Materia Medica

Ryan CAWOOD
Ryan CAWOOD

Chief Scientific Officer

WuXi Advanced Therapies

 Lei ZHANG
Lei ZHANG

R&D VP

Neukio Biotherapeutics

Jimin GAO
Jimin GAO

Professor

Wenzhou Medical University

Ke ZHANG
Ke ZHANG

Chief Scientific Officer

SCG Cell

Yun YANG
Yun YANG

CTO

CirCode Bio

Yang WANG
Yang WANG

Director of Research and Development

Wuhan Binhui Biopharmaceutical

Xiaoxi XU
Xiaoxi XU

Director of In Vitro

Crown Bioscience

Mark FANG
Mark FANG

CQO

Shanghai Zhimi Medical Technology

Adam ZHAO
Adam ZHAO

President

AnlongBio

Yunxiang ZHU
Yunxiang ZHU

Vice President

CANbridge Pharma

Frank GAO
Frank GAO

Chief Strategy Officer

BRL Medicine

Tianhong XU
Tianhong XU

CEO

Base Therapeutics

Emily TAN
Emily TAN

Chief Operating Officer

Bennu Biotherapeutics

Fred MAO
Fred MAO

Partner & Managing Director

Frost & Sullivan

Yarong LIU
Yarong LIU

Founder

Grit Biotechnology

Lei SUN
Lei SUN

CTO

GeneMind

John LU
John LU

President & CEO

HebeCell

Yi ZHU
Yi ZHU

Chief Executive Officer

Hillgene

Grace Zhou
Grace Zhou

CEO

ImmVira Pharma

Xiaoqi QI
Xiaoqi QI

Associate Regional Marketing Manager

10x Genomics

Ways to Attend

Increase Your Visibility. Improve Your Reputation

Normal Ticket

  • 1 Pass

  • 2 Networking Buffet Lunch

  • Simultaneous Interpretation

  • PPTs & Documentation


Exhibition Sponsor

  • 3 Passes

  • 6㎡or 9㎡ Booth for show

  • Holistic Logo Branding On-site

  • 2 Networking Buffet Lunch

  • Simultaneous Interpretation

  • PPTs& Documentation


Presentation Sponsor

( Slots Limited)

  • 5 Passes

  • 30 min Speech Opportunity

  • 1 Color AD Page

  • Panelist Discussion

  • Holistic Logo Branding On-site

  • 2 Networking Buffet Lunch

  • Simultaneous Interpretation

  • PPTs& Documentation


Gold Sponsor

(Exclusive)

  • 5 or More Passes

  • 30 min Speech Opportunity

  • 6or 9 Booth for show

  • Chairman Opportunity

  • 1 Color AD Page

  • Panelist Discussion

  • Holistic Logo Branding On-site

  • 2 Networking Buffet Lunch

  • Simultaneous Interpretation

  • PPTs& Documentation


Secure your ticket today

Early Bird tickets available now

Secure your spot at CGT Asia our special offer, and don’t go alone, enjoy the best group discount.

Register

Sponsors & Partners

Part of Media Partners

今日头条
搜狐
药智网
医谷网
CPHI制药在线
会会药咖
镁客网
化学加
人民医生网
研发客
肽度
大健康派
生物探索
药源网
基因线上
转化医学网
现代健康网
医药健闻
中国制药设备网
环球财经
商业观察网
医诺医学
美通社
动脉网
医疗器械创新网
化学网
中国仪器批发网
再生医学
盖德化工网
大健康网
阿仪网
张通社
测序宝
基因君
51健康网
中国健康咨询网
爱爱医
来宝网
露森科研
生物通
医学信息
中国生物器材网
分析测试百科网
全球医学会议网

Related Meetings

Presentation, Sponsorship and Exhibition

Gina Xu

Tel:86 21 5893 3801 ext.805

Mob:13601679417

Email:gina.xu@taaslabs.com

Media and Marketing Cooperation

Koala Yan

Tel:86 215893 3801 ext. 811

Mob:13341683667

Email:koala.yan@taaslabs.com

Know More Hot and informative Medical News on Biopharma, Cell& Gene etc. Follow Us Now